211 related articles for article (PubMed ID: 34269904)
61. Wee1 inhibition can suppress tumor proliferation and sensitize p53 mutant colonic cancer cells to the anticancer effect of irinotecan.
Yin Y; Shen Q; Tao R; Chang W; Li R; Xie G; Liu W; Zhang P; Tao K
Mol Med Rep; 2018 Feb; 17(2):3344-3349. PubMed ID: 29257266
[TBL] [Abstract][Full Text] [Related]
62. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.
Lee JW; Parameswaran J; Sandoval-Schaefer T; Eoh KJ; Yang DH; Zhu F; Mehra R; Sharma R; Gaffney SG; Perry EB; Townsend JP; Serebriiskii IG; Golemis EA; Issaeva N; Yarbrough WG; Koo JS; Burtness B
Clin Cancer Res; 2019 Jun; 25(11):3430-3442. PubMed ID: 30755439
[TBL] [Abstract][Full Text] [Related]
63. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
[TBL] [Abstract][Full Text] [Related]
64. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.
Clausse V; Goloudina AR; Uyanik B; Kochetkova EY; Richaud S; Fedorova OA; Hammann A; Bardou M; Barlev NA; Garrido C; Demidov ON
Cell Death Dis; 2016 Apr; 7(4):e2195. PubMed ID: 27077811
[TBL] [Abstract][Full Text] [Related]
65. Targeting Wee1 for the treatment of pediatric high-grade gliomas.
Mueller S; Hashizume R; Yang X; Kolkowitz I; Olow AK; Phillips J; Smirnov I; Tom MW; Prados MD; James CD; Berger MS; Gupta N; Haas-Kogan DA
Neuro Oncol; 2014 Mar; 16(3):352-60. PubMed ID: 24305702
[TBL] [Abstract][Full Text] [Related]
66. AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells.
Webster PJ; Littlejohns AT; Gaunt HJ; Prasad KR; Beech DJ; Burke DA
Cell Cycle; 2017; 16(22):2176-2182. PubMed ID: 28296564
[TBL] [Abstract][Full Text] [Related]
67. Targeting WEE1 Kinase in Cancer.
Matheson CJ; Backos DS; Reigan P
Trends Pharmacol Sci; 2016 Oct; 37(10):872-881. PubMed ID: 27427153
[TBL] [Abstract][Full Text] [Related]
68. Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis.
Bukhari AB; Lewis CW; Pearce JJ; Luong D; Chan GK; Gamper AM
J Clin Invest; 2019 Mar; 129(3):1329-1344. PubMed ID: 30645202
[TBL] [Abstract][Full Text] [Related]
69. Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the
Iannuzzi CA; Indovina P; Forte IM; Di Somma S; Malfitano AM; Bruno M; Portella G; Pentimalli F; Giordano A
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33020398
[TBL] [Abstract][Full Text] [Related]
70. Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
Leijen S; van Geel RM; Sonke GS; de Jong D; Rosenberg EH; Marchetti S; Pluim D; van Werkhoven E; Rose S; Lee MA; Freshwater T; Beijnen JH; Schellens JH
J Clin Oncol; 2016 Dec; 34(36):4354-4361. PubMed ID: 27998224
[TBL] [Abstract][Full Text] [Related]
71. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
[TBL] [Abstract][Full Text] [Related]
72. Development and Characterization of a Wee1 Kinase Degrader.
Li Z; Pinch BJ; Olson CM; Donovan KA; Nowak RP; Mills CE; Scott DA; Doctor ZM; Eleuteri NA; Chung M; Sorger PK; Fischer ES; Gray NS
Cell Chem Biol; 2020 Jan; 27(1):57-65.e9. PubMed ID: 31735695
[TBL] [Abstract][Full Text] [Related]
73. Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.
Indovina P; Marcelli E; Di Marzo D; Casini N; Forte IM; Giorgi F; Alfano L; Pentimalli F; Giordano A
Cancer Biol Ther; 2014 Apr; 15(4):380-8. PubMed ID: 24365782
[TBL] [Abstract][Full Text] [Related]
74. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.
Hirai H; Arai T; Okada M; Nishibata T; Kobayashi M; Sakai N; Imagaki K; Ohtani J; Sakai T; Yoshizumi T; Mizuarai S; Iwasawa Y; Kotani H
Cancer Biol Ther; 2010 Apr; 9(7):514-22. PubMed ID: 20107315
[TBL] [Abstract][Full Text] [Related]
75. PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer.
Brunner A; Suryo Rahmanto A; Johansson H; Franco M; Viiliäinen J; Gazi M; Frings O; Fredlund E; Spruck C; Lehtiö J; Rantala JK; Larsson LG; Sangfelt O
Elife; 2020 Jul; 9():. PubMed ID: 32628111
[TBL] [Abstract][Full Text] [Related]
76. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
Garcia TB; Fosmire SP; Porter CC
Leuk Res; 2018 Jan; 64():30-33. PubMed ID: 29175378
[TBL] [Abstract][Full Text] [Related]
77. Cytokinetic effects of Wee1 disruption in pancreatic cancer.
Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D
Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070
[TBL] [Abstract][Full Text] [Related]
78. Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target.
Aka Y; Karakas B; Acikbas U; Basaga H; Gul O; Kutuk O
Int J Biochem Cell Biol; 2021 Aug; 137():106028. PubMed ID: 34171479
[TBL] [Abstract][Full Text] [Related]
79. Targeting the checkpoint kinase WEE1: selective sensitization of cancer cells to DNA-damaging drugs.
Indovina P; Giordano A
Cancer Biol Ther; 2010 Apr; 9(7):523-5. PubMed ID: 20150761
[No Abstract] [Full Text] [Related]
80. Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.
Caiola E; Frapolli R; Tomanelli M; Valerio R; Iezzi A; Garassino MC; Broggini M; Marabese M
Sci Rep; 2018 Jan; 8(1):948. PubMed ID: 29343688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]